EXPERIENCE OF USING THE TB DRUG OF PERCHLOZON IN TUBERCULOSIS PATIENTS WITH MULTIPLE DRUG RESISTANCE IN BURYATIA REPUBLIC

Abstract

Lately the main TB epidemiological rates are becoming stable in Buryatia Republic. In 2013-2014 the e¾ciency of use of perchlozon was studied within integral treatment of pulmonary tuberculosis patients with multiple and extensive drug resistance (MDR and XDR TB). The first group (n = 28) where the combination of standard regimen 4 with perchlozon was used included patients 85.7% of them with chronic tuberculosis with MDR and XDR. The patients from the second group (n = 30) were treated by standard regimen 4. 78.6% of patients treated by regimens with perchlozon had XDR TB with resistance to second line drugs (p < 0.01). The second group was resistant mostly to 3 main drugs – 66.7% of patients, and there were single cases of resistance to fluoroquinolones. The tolerance of perchlozon was not significantly di|erent from tolerance of the second line TB drugs. The treatment allowed achieving positive clinical changes in the patients' state up to complete elimination of intoxication symptoms and reduction of respiratory insu¾ciency with simultaneous X-ray regression of inflammatory changes in the lungs by the moment of transfer to the continuation phase, it was more often observed in the second group in 22 (73.3%) patients compared to 12 (42.9%) of the first group (p < 0.05). In 4 months of treatment the smear converted in 10 (35.8%) patients from the first group compared to 17 (56.6%) patients from the second group. The use of perchlozon in the complex treatment of XDR tuberculosis patients, in whom there is no favorable prognosis of tuberculosis cure, allows confident clinical and X-ray stabilization of the chronic tuberculosis disease in 42.9% and sputum conversion in 35.8% of patients from the 1st group.

Keywords

• tuberculosis
• multiple drug resistance
• extensive drug resistance
• perchlozon